NEW YORK, NY — (Marketwire) — 11/18/09 — Vivakor, Inc. (OTCBB: VIVK) announced yesterday that its Board of Directors approved a dividend to share holders of record for December 1, 2009. Each shareholder will receive one (1) share of HealthAmerica, Inc. for every one (1) share of Vivakor, Inc. pending FINRA approval.

HealthAmerica, Inc. is in the process of developing a patented magnetic resonance imaging (MRI) image resolution enhancing technology called VIVASlices. With the sales of all medical devices slowing, a need for clearer more efficient machines is arising. With the decrease in sales of medical devices like MRIs, facilities are demanding more out of their machines and require them to produce better results.

It is estimated there are between 7,000 and 10,000 MRI machines in use in the United States alone. VIVASlices with its easy to use user interface will work on low, mid and high field magnets, opening

Nov. 17, 2009 (PR Newswire) — CORALVILLE, Iowa, Nov. 17 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced that its Board of Directors approved a dividend of shares of common stock of HealthAmerica, Inc., a Nevada corporation of which Vivakor owns approximately 84% of the outstanding common stock. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on the record date. The record date for the distribution is expected to be December 1, 2009, subject to review and approval of FINRA, and the distribution date is expected to be December 9, 2009. After the dividend distribution, Vivakor will continue to own approximately 62% of the outstanding common stock of HealthAmerica.

Vivakor shareholders will not be required to take any action to receive the HealthAmerica common shares on the distribution date.

Vivakor Chairman Matt Nicosia

Nov. 12, 2009 (PR Newswire) — CORALVILLE, Iowa, Nov. 12 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) is the keynote presenting company at the founders’ celebration of consumer product specialist, Regeneca International, Inc. (www.regeneca.com). The celebration will be attended by over 200 founders and guests of Regeneca International from across the United States. It will be hosted at the prestigious Balboa Bay Club in Newport Beach, California. Vivakor’s Chairman, Matt Nicosia and CFO, Ed Corrente will both be attending the event.

Event attendee, Dr. Brian Scott , a Regeneca advisory board member and nationally recognized wellness expert, was particularly pleased to learn of Vivakor’s role in the event. “As a healthcare provider and speaker on issues regarding wellness and longevity, it is refreshing to hear the perspective of a company, doing business internationally, which can provide a particular focus on products which extend the length and

Nov. 11, 2009 (Business Wire) — Vivakor, Inc. (OTCBB: VIVK) today announced it has completed an exclusive distribution agreement with consumer product specialist, Regeneca International, Inc. (www.regeneca.com) for one of its proprietary, cutting-edge nutraceutical formulations. In conjunction with this agreement was an immediate purchase order from Regeneca for 25,000 units of the product. Both companies hope this agreement initiates a long term relationship for product commercialization. This purchase also represents to another substantial revenue stream for Vivakor’s emerging nutraceutical division. Vivakor CEO Tannin Fuja expressed his enthusiasm for the transaction. “We are very excited for the possibilities of Vivakor’s line of nutraceutical products. Worldwide demand for nutraceutical products is expected to exceed $15 billion and Vivakor plans on being a substantial player in that market.”

Dr. Fuja continued, “We are particularly pleased to include in our new formulation the powerful, super-antioxidant star Yumberry (yang-mei in Chinese) also

Nov. 9, 2009 (Business Wire) — Vivakor, Inc. (OTCBB: VIVK) today announced it has completed a pilot product evaluation program with consumer product specialist, Regeneca International, Inc. (www.regeneca.com). The product evaluation involved Vivakor’s proprietary nutraceutical formulation derived from natural sources. Research has shown that phytochemicals, vitamins, minerals, and fiber, all present in fruits and vegetables, work synergistically to promote health and lower disease risk. For this reason, many organizations, such as the National Cancer Institute and The American Heart Association, recommend getting phytochemicals from whole foods, such as fruits and vegetables. The Vivakor product is a whole food supplement designed to deliver these essential nutrients to the users in small, single dose units.

Regeneca’s President, Larry Walter gave his thoughts on the study. “Not only are the consumer study results impressive, but the overall opportunity to work with the team of professionals at Vivakor gives us a great deal

Oct. 8, 2009 (Business Wire) — Vivakor, Inc. (OTCBB: VIVK) announces distribution of its VivaThermic products to the rapidly growing biotech/biopharma industries in India through its agreement with Pro Lab Marketing Pvt. Ltd. This agreement gives Pro Lab Marketing distribution rights for Vivakor’s VivaThermic cryovials in India. Pro Lab Marketing, based in New Delhi, is a well-established Indian supplier of biotechnology-related products and equipment throughout India. “We are impressed with the VivaThermic products and their outstanding performance,” stated Mr. J.K. Jain, Managing Director of Pro Lab Marketing. He continues, “Through our distribution agreement with Vivakor we will introduce the VivaThermic products to our customers throughout India who will benefit greatly from use of this technology.”

Vivakor’s CEO, Dr. Tannin Fuja, indicated that, “The Indian biotechnology industry is gaining significant momentum and India figures to become a prominent player in the global biotech market. A number of India’s biotech firms

A surprising decline in home sales and another sharp drop in oil prices are driving investors to sell stocks.

At midday, the Dow Jones industrials fell 46.02, or 0.5 percent, to 9,702.53. The Standard & Poor’s 500 index fell 9.32, or 0.9 percent, to 1,051.55, and the Nasdaq composite index fell 25.19, or 1.2 percent, to 2,106.23.

Shares of VIVK are under heavy accumulation today as more than 85,000 shares have traded at midday as compared to its 10-day average of only 5,500 shares.

Vivakor an up and coming biomedical/biotechnology company with trans-disciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life.

The R&D Core at Vivakor (the idea hub) innovates, develops and validates biomedical devices and biotechnologies. Commercialization of Vivakor technologies is accomplished through partnerships with